performance score (KPS), the extent of surgical removal, reoperation for recurrent tumors, neurologic symptoms and the duration of disease (4) (5) (6) (7) (8) . The reported image prognosis factors are the preoperative MR imaging characteristics of the tumor and the associated grade of necrosis, with edema, enhancement and necrosis being the most important histological prognostic factors (4, 8) . Hammoud et al demonstrated that patients with little or no necrosis survive longer than those patients with profuse necrosis seen on the preoperative MRI scans, and Maldaun et al recently revealed that the patients with GBMs that included cystic components had a more favorable survival outcome than those patients without cysts (4, 9) . Several authors have mentioned the clinical differences between the cystic and necrotic changes in GBMs; however, it is difficult to distinguish cystic change from necrotic changes within tumors and there is little published data related to the different MRI features between cystic GBMs and noncystic GBMs. The purpose of this study was to determine the preoperative radiological characteristics and survival differences of GBMs with and without cysts.
Materials and Methods

Patient Population
We retrospectively reviewed the medical records and diagnostic images to obtain information on the study patients. We identified 24 patients who were diagnosed with GBMs and who were treated between January 2000 and March 2009. A review of the patients' charts was conducted to obtain information on their ages, gender, KPS and treatment. The patients underwent total or subtotal mass removal and stereotactic biopsy of a histologically confirmed supratentorial glioblastoma according the World Health Organization (WHO) classification. Preoperative MRI images had been obtained for all the patients. The three patients with incomplete or poor quality preoperative imaging data were excluded from the analysis; the remaining 21 patients made up the study population: there were 12 males and 9 females with a mean age of 46 years (range: 15-80).
Imaging Protocol
All the MRI images were obtained with a 1.5-T MR imaging unit, Magnetom Vision (Siemens Medical Systems, Erlangen, Germany). The MRI protocol included the following pulse sequences: the axial T1-weighted and axial fast spin-echo T2-weighted MR images. The contrast agent-enhanced T1-weighted images were obtained in all patients after intravenous injection of 0.1 mmol per kilogram of body weight gadolinium-based contrast agent (Gadoterate meglumine, Dotarem, Guerbet, Paris, France; or gadodiamide, Omniscan, GE Healthcare, Belfast, Ireland).
Definition of Variables
The preoperative MR images of all the patients were retrospectively reviewed and several imaging features were identified. Our criteria for the radiologic diagnosis of a cyst on an MRI scan were the appearance of an area of well defined, spherical or ovoid lesions with an even lining. Necrosis was defined as an area of irregular bordered components within the tumors, which had decreased signal intensity on a T1-weighted MRI scan and this was surrounded by a contrast enhanced tumor nodule (4, 10, 11) . In all cases, we regarded cystic tumor as a mass contained a cystic component, based on the preoperative MR imaging study. The cystic portion of the tumor showed an ovoid or spherical shape, a well defined interface, homogeneous hypointensity, an enhanced even lining and a thin, smooth wall on the Gd-enhanced T1-weighted MR images (Fig. 1) . On the other hand, noncystic GBM showed an irregular shape, poor interface and an enhanced thick, uneven wall on the Gd-enhanced T1-weighted MR images (Fig. 2) .
The tumor volume on the MRI appears as a maximal enhanced area from the post-contrast T1-weighted image with using 3D volume reconstruction. Tumor interface was defined as the interface between the tumor and peritumoral brain parenchyma and this was classified as a well defined or poorly defined interface. Tumor wall thickness was calculated by the mean value between the maximum and minimum width on the contrast-enhanced T1-weighted images. Peritumoral edema on the MRI appears as a region of increased signal intensity of the extratumoral infiltrative portion outside the tumor on the T2-weighted image. Intratumoral hemorrhage was considered as the high signal area on the T2-& T1-weighted MR images without definite contrast enhancement on the contrast-enhanced T1-weighted MR images. The tumor resection rate was obtained by measuring the difference of tumor volume on the pre and postoperative brain MRI. The volume assessments of the mass or the peritumoral edema were performed by use of the commercial 3D reconstruction computer program (Aquarius, intuition edition, version 4.4, Terarecon, USA).
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Statistical Methods
The Mann-Whitney U test and the chi-square test were used to assess the differences in patient age between the cystic and noncystic GBMs. Fisher's exact test was used to assess the differences in tumor size, peritumoral edema and tumor interface irregularity between the cystic and noncystic GBMs. The KaplanMeier method was used to estimate the progression free survival parameters and log-rank tests were performed to determine any statistically significant differences between the groups. All the statistical analyses were performed by using the SPSS/PC_ version 15.0 software (SPSS, Seoul, Korea). For all evaluations, p values <0.05 were considered statistically significant.
Results
Seven cases were classified as cystic GBMs and fourteen were noncystic GBMs. The cystic GBM group consisted of three men and four women, and the noncystic GBM group included nine men and five women. Table  1 summarizes the results of the statistical differences between the cystic and noncystic GBM groups. There was a statistically significant difference in age (MannWhitney U test; p <0.05) between the cystic GBM group (mean age: 34 years, range: 2-18 years) and the noncystic GBM group (mean age: 52 years, range: 26-81 years). The median and range of the preoperative and postoperative KPS of the cystic GBM patient were 70, 30-80 and 70, 40-80, respectively. The median and range of the preoperative and postoperative KPSs of the noncystic GBM patient were 60, 30-80 and 65, 40-90, respectively.
The tumor volume was calculated to be more than 70 cm 3 in four of the seven cystic GBM patients (57%) and in four of the fourteen noncystic GBM patients (28%). Six cystic GBM patients (85%) had a well defined interface between the tumor and the normal brain tissue. The non cystic GBM shows an irregular shape, a poor interface and an enhanced thick and uneven wall on the Gd-enhanced T1-weighted MR images.
The micrographs of the cystic GBM patients showed bizarre tumor cells with abundant eosinophilic cytoplasm and these cells were found in an edematous stroma. The pleomorphic tumor cells showed variations of size and shape. The large tumor cells had abundant eosinophilic cytoplasm with fibrillary processes (Fig. 2) .
The other GBMs had poorly defined interfaces with tumor cells infiltrating into the brain parenchyma. The tumoral wall thickness was less than 2 cm in six of the seven cystic GBM patients (85%) and in three of the fourteen noncystic GBM patients (22%). The peritumoral edema was calculated to be less than 40 cm 3 in five of the seven cystic GBM patients (71%) and in two of the fourteen noncystic GBM patients (14%). Two cystic GBM patients (28%) and eight noncystic GBM patients (56%) showed intratumoral hemorrhage. All the cystic GBMs and 71% of the noncystic GBM patients received tumor resection. The median and range of the resection rate of cystic GBM patients were 78% and 53~98%, respectively. The median and range of the resection rate of the noncystic GBM patient were 79% and 25~100%, respectively. Five cystic patients and six noncystic patients received combined radiotherapy and chemotherapy, respectively. The other two and four cystic and noncystic GBM patient underwent radiotherapy alone.
In summary, the cystic and noncystic GBMs differed significantly for peritumoral edema, the tumor interface and the tumor wall thickness (Fisher's exact test; p < 0.05), but there was no significant difference for tumor volume and intratumoral hemorrhage ( Table 1 ). The postoperative cumulative survival outcomes for the GBMs groups are shown in Table 2 . For those with cystic GBMs, the 6-month, 1-year, 2-year and 3-year cumulative survival rates were 100%, 100%, 67% and 50%, respectively. For the patients with noncystic GBMs, the 6-month, 1-year, 2-year and 3-year cumulative survival rates were 69%, 49%, 14% and 7%, respectively. For the 3) .
Discussion
Glioblastomas have historically been classified as primary or secondary. The terms primary and secondary glioblastomas were first used by the German neuropathologist Hans-Joachim Scherer (12) . Primary GBMs have been termed de novo. This term refers to the lack of a precursor lesion resulting from a single-step malignant transformation. Secondary GBMs has been referred to as progressive GBM. They develop by malignant progression from a low-grade astrocytoma or anaplastic astrocytoma. The development time varies from months to years. Primary and secondary GBMs are distinct entities according to their different genetic pathways, the associated patient ages and the different responses to therapy. Based on genetic typing, some authors also refer to primary and secondary glioblastomas as glioblastoma types 2 and 1 (9, (12) (13) (14) . Several authors have studied the difference between primary and secondary GBMs as related to the genetic pathways and the clinical and radiologic features. Kleihues and Ohgaki have classified primary and secondary GBMs by the different genetic types and they found that secondary GBMs tend to develop at a younger age. For the radiologic features, the existence and nonexistence of necrosis and cystic formation is an important factor to evaluate the subtypes of GBMs. In general, approximately 10% of the tumors of the CNS are accompanied by a cystic area (15) . There is a growing interest in the cystic lesions that accompany brain tumors. A cyst is commonly found in low-grade astrocytomas and in most pilocytic astrocytomas. The cause of cyst formation re- mains controversial. One hypothesis has claimed that large cysts are malignant transformations of previously undiagnosed cystic low-grade glioma. Laws et al reported that the low grade astrocytomas that include cysts have a better prognosis (16) . According to Satoshi et al, the prognosis for cystic GBMs was significantly better than that for noncystic GBMs. They reported that cystic GBM patients were significantly younger than the non cystic GBM patients (13) . Other studies have concluded that the secondary GBM patients are younger than the primary GBM patients (12) . These observations suggest that most of the cystic GBMs have clinical features that are like those of secondary GBMs. Accordingly, it has been postulated that the large cysts accompanying tumors develop by malignant transformation from undetected low-grade glioma. Other hypotheses to explain the presence of cysts in GBMs include necrotic degeneration of brain tissue or blood-brain barrier (BBB) disruption. Maldaun et al revealed that the cystic patients' clinical characteristics such as age and the clinical manifestations differ from the previously published data about GBMs and they were not the same as the features of secondary GBM (a long preoperative clinical history and younger patients). Accordingly, no clinical data has been found to support the hypothesis of malignant transformation (8-10, 17, 18) . In addition, Lohle et al modified the second hypothesis in several of their studies. In the past literature, it was believed that tumor cyst formation was caused by degeneration or necrosis of tumor tissue. The postulated hypothesis of intratumoral cyst formation is secretion of fluid by the tumor cells and cystic degenerative change within the tumor. However, the more recent reports by Lohle et al have suggested that cyst formation is due to an edematous process caused by BBB disruption and it is not the result of necrosis, based on the chemical assessment. This hypothesis proposes that cyst formation is caused by exudation of blood plasma proteins and the accumulation of interstitial fluid in the brain parenchyma. Lohle et al revealed a high protein concentration in the cysts with a highly similar spectrum of proteins in the tumor cyst fluid and the blood plasma. Brain tumor cyst fluid analysis found that blood plasma proteins constituted a major fraction (92%) of the tumor cyst fluid proteins. Fifty-fold higher concentrations of proteins were present in the tumor cyst fluid compared with that of the cerebrospinal fluid. This data suggests there is increased barrier permeability due to BBB disruption followed by exudation of plasma proteins into the brain parenchyma with formation of edema and the transition of the edematous tissue into cystic tumors (11, 19, 20) .
Most GBMs have massive edema in the peritumoral area. This edema is due to the infiltration of tumor cells into the white matter and the mass effect of the tumors themselves. Vasogenic edema is caused by exudation of blood plasma proteins and the accumulation of interstitial fluid in the brain parenchyma through a damaged BBB, and this is similar to that producing cyst formation. According to Satoshi et al, cystic GBMs had smaller peritumoral edema regions and sharper boundaries than did the noncystic GBMs. Sawaya et al revealed a significant correlation between tPA (tissue plasminogen activators) and the presence and amount of peritumoral edema (21) . Our study revealed that the cystic GBM patients were significantly younger and they had more favorable survival outcomes than did the patients with noncystic GBMs. This is similar to Satoshi's results. They reported the prognosis for cystic GBM was significantly better than that for noncystic GBM and the cystic GBM patients were significantly younger than the non cystic GBM patients (13) . These observations suggest that most of the cystic GBMs have clinical features that are similar to those of secondary GBMs. However, this is not good evidence that cystic GBMs are secondary GBMs. This hypothesis additionally could be tested by looking at the gene expression and the IDH1 mutation status.
This study has some limitations. First, it is designed to retrospectively collect data from the preoperative MR images and medical records. A small patient population was enrolled in this study. As mentioned earlier, it is difficult to distinguish cysts with necrosis, regardless of our several criteria. We also had some problems measuring the edema in some cases of infiltrating tumors due to the indistinct separation between the tumor and the surrounding edema.
In conclusion, the cystic GBMs had a well-defined tumor interface, a thin wall and minimal edema as compared with the noncystic GBMs. The cystic GBM patients were significantly younger than the noncystic GBM patients. In addition, our analysis demonstrated that the patients with cystic GBMs had more favorable survival outcomes than did the patients with noncystic GBMs.
